CTRI/2022/08/045031尚未招募未知
Feasibility of ââ?¬Å?1-3-7ââ?¬? surveillance and response approach for malaria elimination in urban Udupi: a mixed method study
Manipal Centre for Infectious Diseases0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Health workers working in government facilities like, Primary Health Centres and Urban Health centres and DVBDCP office will be included in to the study.
排除标准
- 未提供
研究者
相似试验
已完成
不适用
Establishment of the surveillance system exploring risk factors for emergency transportation outside a remote island.chronic illness, osteoporosis, and patients with potentially high risk for emergency admissions.JPRN-UMIN000033313The Institute of Medical Science, the University of Tokyo2,000
已完成
不适用
Establishment of surveillance system for the longstanding ulcerative colitis patients Comparative study of efficacy for the targeted biopsy and the step biopsylcerative colitisJPRN-UMIN000001608Teikyo University School of Medicine200
进行中（未招募）
1 期
A research study to collect long term safety information from subjects who have received study treatment from a qualifying lenabasum Corbus trial.Dermatomyositis (DM) is a rare and serious autoimmune disease.An overactive immune response causes chronic inflammation,which results in growth of scar tissue in the skin,muscles,and many internal organs.Cystic Fibrosis (CF) is a genetic disorder which results in thick mucus formation on the airways leading to increased lung infections,fibrosis of the lungs and digestive tract and abnormal immune functionMedDRA version: 20.0Level: PTClassification code 10012503Term: DermatomyositisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 20.0Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-001762-11-HUCorbus Pharmaceuticals, Inc.100
进行中（未招募）
1 期
A research study to collect long term safety information from subjects who have received study treatment from a qualifying lenabasum Corbus trial.EUCTR2020-001762-11-GBCorbus Pharmaceuticals, Inc.100
进行中（未招募）
1 期
A research study to collect long term safety information from subjects who have received study treatment from a qualifying lenabasum Corbus trial.Dermatomyositis (DM) is a rare and serious autoimmune disease.An overactive immune response causes chronic inflammation,which results in growth of scar tissue in the skin,muscles,and many internal organs.Cystic Fibrosis (CF) is a genetic disorder which results in thick mucus formation on the airways leading to increased lung infections,fibrosis of the lungs and digestive tract and abnormal immune functionMedDRA version: 20.0Level: PTClassification code 10012503Term: DermatomyositisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 20.0Level: PTClassification code 10011762Term: Cystic fibrosisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-001762-11-SECorbus Pharmaceuticals, Inc.100